VIVUS (VVUS) Lower Heading into Obesity 2012 Event; Will Present New Qsymia Data
Tweet
Share
E-mailGet Alerts VVUS Hot Sheet
Join SI Premium – FREE
VIVUS, Inc. (Nasdaq: VVUS) shares are trading lower amid the company presenting new Qsymia data at an industry event later on Monday.
According to a prior release, VIVUS will present multiple scientific abstracts at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society, to be held September 20th to September 24th in San Antonio, Texas. The presentations will be made from noon to 1:30pm EDT (1:00pm to 2:30pm EDT).
Notably, Qsymia was recently announced for the U.S. market, though its having trouble clearing the hurdle in Europe.
The five posters are:
According to a prior release, VIVUS will present multiple scientific abstracts at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society, to be held September 20th to September 24th in San Antonio, Texas. The presentations will be made from noon to 1:30pm EDT (1:00pm to 2:30pm EDT).
Notably, Qsymia was recently announced for the U.S. market, though its having trouble clearing the hurdle in Europe.
The five posters are:
- Title: Weight Loss and Reduction in Unique Antidiabetic Medication Use in Obese Subjects With Type 2 Diabetes Mellitus Using Extended-Release Phentermine/Topiramate Over 2 YearsLead Authors: T. GarveyPoster Number: 459-P
- Title: Weight Loss by Degree of Comorbidity as Assessed by the Edmonton Obesity Staging System in Subjects Receiving Extended-Release Phentermine/TopiramateLead Author: L. J. CheskinPoster Number: 460-P
- Title: Weight Loss and Changes in Blood Pressure and Triglycerides by Degree of Comorbidity in Subjects Receiving Extended-Release Phentermine/Topiramate Lead Author: A. M. SharmaPoster Number: 461-P
- Title: Reduction in Cardiovascular Risk Associated With Weight Loss in Three Clinical Trials of Obese Subjects Receiving Extended-Release Phentermine/TopiramateLead Author: T. Church Poster Number: 462-P
- Title: Application of Proposed Treatment Algorithm Improves the Benefit/Risk Profile of Phentermine Plus Extended-Release TopiramateLead Authors: R. DvorakPoster Number: 34-LB-P
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
- Creative Medical completes enrollment in ADAPT back pain trial
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
Create E-mail Alert Related Categories
FDA, Insiders' BlogSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
